The latest price target for Sartorius Stedim Biotech (OTCPK:SDMHF) was reported by Societe Generale on October 1, 2021. The analyst firm set a price target for $0.00 expecting SDMHF to fall to within 12 months (a possible NaN% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Sartorius Stedim Biotech (OTCPK:SDMHF) was provided by Societe Generale, and Sartorius Stedim Biotech downgraded their hold rating.

There is no last upgrade for Sartorius Stedim Biotech

The last downgrade for Sartorius Stedim Biotech SA happened on October 1, 2021 when Societe Generale changed their price target from N/A to N/A for Sartorius Stedim Biotech SA.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sartorius Stedim Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sartorius Stedim Biotech was filed on October 1, 2021 so you should expect the next rating to be made available sometime around October 1, 2022.

While ratings are subjective and will change, the latest Sartorius Stedim Biotech (SDMHF) rating was a downgraded with a price target of $0.00 to $0.00. The current price Sartorius Stedim Biotech (SDMHF) is trading at is $undefined, which is out of the analyst’s predicted range.